Background When an outcome of interest in a clinical trial is late-occurring or difficult to obtain, surrogate markers can extract information about the effect of the treatment on the outcome of interest. Understanding associations between the causal effect (CE) of treatment on the outcome and the causal effect of treatment on the surrogate is critical to understanding the value of a surrogate from a clinical perspective. Purpose Traditional regression approaches to determine the proportion of the treatment effect explained by surrogate markers suffer from several shortcomings: they can be unstable and can lie outside the 0-1 range. Furthermore, they do not account for the fact that surrogate measures are obtained post randomization, and thus, the surrogate-outcome relationship may be subject to unmeasured confounding. Methods to avoid these problems are of key importance. Methods Frangakis and Rubin suggested assessing the CE within prerandomization 'principal strata' defined by the counterfactual joint distribution of the surrogate marker under the different treatment arms, with the proportion of the overall outcome CE attributable to subjects for whom the treatment affects the proposed surrogate as the key measure of interest. Li et al. developed this 'principal surrogacy' approach for dichotomous markers and outcomes, utilizing Bayesian methods that accommodated nonidentifiability in the model parameters. Because the surrogate marker is typically observed early, outcome data are often missing. Here, we extend Li et al. to accommodate missing data in the observable final outcome under ignorable and nonignorable settings. We also allow for the possibility that missingness has a counterfactual component, a feature that previous literature has not addressed. Results We apply the proposed methods to a trial of glaucoma control comparing surgery versus medication, where intraocular pressure (IOP) control at 12 months is a surrogate for IOP control at 96 months. We also conduct a series of simulations to consider the impacts of nonignorability, as well as sensitivity to priors and the ability of the decision information criterion (DIC) to choose the correct model when parameters are not fully identified. Limitations Because model parameters cannot be fully identified from data, informative priors can introduce nontrivial bias in moderate sample size settings, while more noninformative priors can yield wide credible intervals. Conclusions Assessing the linkage between CEs of treatment on a surrogate marker and CEs of a treatment on an outcome is important to understanding the value of a marker. These CEs are not fully identifiable; hence, we explore the sensitivity and identifiability aspects of these models and show that relatively weak assumptions can still yield meaningful results.
Introduction
Given the time required to obtain clinical endpoints such as survival, there is interest in using surrogate endpoints such as disease-free survival at early follow-up periods [1] or biomarkers such as CD4 counts for AIDS [2] to assess the effectiveness of a treatment regime in clinical trial settings. The demand for 'surrogate markers' in clinical research has led to the development of a large number of statistical methods to evaluate the effectiveness of such measures [3] . Prentice's [4] foundational article defined 'perfect' surrogacy in the hazard regression setting as occurring when an outcome T is independent of treatment Z conditional on the surrogate measure S. Freedman et al. [5] pointed out that this is an extremely strict criterion rarely met in practice and suggested as an alternative measure in the absence of a surrogate-treatment interaction the proportionate reduction of the treatment effect on a binary outcome when the surrogate measure is included in a logistic regression model. This 'proportion-explained' estimator itself had shortcomings, including the fact that it can be unstable, and can lie outside of the 0-1 range [6, 7] . Thus, a meta-analytic approach to assess surrogacy has been suggested by Buyse et al. [8] , who distinguish between trial-level and individual-level surrogacy and use random effects models to assess the variance of a predicted association between treatment and outcome in a new trial at both the individual and trial level when only the effect of treatment on a surrogate has been measured. Small variances in these associations (i.e., large coefficients of determinations) at both the individual and trial level are indicative of a good surrogate measure.
An alternative approach to assessing surrogacy uses causal inference, with the goal of understanding causal links between treatment, surrogate, and outcome. Traditional regression models that condition on surrogacy measures to assess the fraction of the treatment effect explained cannot be viewed as causal if there are confounders between the surrogate marker and the final outcomes, since the surrogate marker is observed post randomization [9] . Thus, Robins and Greenland [10] define direct and indirect effects in mediation analysis in the potential outcomes framework. In this framework, we assume that we can, in principle, observe the values of the outcome under all possible treatment assignments for a given individual. The targets of inference become the differences in the values of the potential outcomes under different treatment assignments within the individual, averaged over the population. Assuming that the surrogate marker can be manipulated independently from the outcome, Robins and Greenland [10] define (natural) direct effects as the expected value of the difference in the potential outcomes under different treatment assignments when the value of the marker is held constant, and define indirect effects as the expected difference in the potential outcomes under treatment when the marker is changed to the value it would have taken under treatment and under control. Assumptions required to obtain identified estimates of direct and indirect effects such as randomization, monotonicity (the treatment is never harmful), and no treatment-mediator interactions can be relaxed in part by sensitivity analyses [11] [12] [13] . An alternative 'principal stratification' approach to assess surrogacy was proposed by Frangakis and Rubin [14] . Principal strata are defined by the joint potential outcomes of the surrogate marker, thus forming a 'pre-randomization' variable that can be conditioned on while retaining causal interpretations of randomized treatment effects. The causal effects (CEs) of interest become the differences in the potential outcomes under treatment and control within the strata in which the surrogate changes as a result of the treatment assignment. This approach has been explored for binary outcomes in more detail by Gilbert and Hudgens [15] and Li et al. [16] , with the former considering categorical and continuous (possibly subject to censoring) markers and focusing on the setting where the marker under the control is fixed and known (allowing identification of model parameters) and the latter focusing on the setting where the marker is also binary (generally allowing identification of parameter boundaries only). Joffe and Greene [17] provide a summary of both the standard regressionbased and the two major causal approaches (which they term as CE and causal association (CA) paradigms, respectively), showing that some of the models developed under the CE paradigm can be recast as CA models, and vice versa.
At the risk of oversimplification, much of the argument between these two approaches revolves around a trade-off between assuming manipulatable variables in the causal pathway between treatment and outcome to allow inference about true causal mechanisms (the CE approach) and sacrificing that mechanistic interpretation for conceptualizations that may be more congruent with the observable data (the CA approach). Recognizing the lively debate about the relative merits of the CE versus CA approaches (see, e.g., Refs [18, 19] or Ref. [20] ) in various settings, we believe the key aspect in surrogacy is the CA. We need to know that the CE of the treatment on the outcome and the CE of the treatment on the marker are 'in sync', so that the marker can predict or replace the outcome in treatment effect estimation. Thus, we proceed with the principal stratification (CA) approach in this article, extending the work of Li et al. [16] to accommodate missing data in the (observable) outcome measure.
Such missing data are a common occurrence in clinical trials since the value of the surrogate variable is typically to provide information in advance of the outcome measure of interest. We utilize the machinery of the missing data literature [21] , focusing on developing a nonignorable missing mechanism for the final outcome of interest on the assigned treatment arm that is based on the assumption of latent ignorability [22] [23] [24] [25] . Latent ignorability assumes an ignorable missingness mechanism conditional on membership in a not fully observable stratum -here the principal strata based on the joint values of the surrogate marker under the differing treatment assignments. In contrast to much of the previous work that assumed latent ignorability in the context of noncompliance in randomized clinical trials, we cannot make 'exclusion restriction' assumptions to force identifiability, since such an assumption would 'assume' the very quantity we are trying to estimate: the degree to which subjects who had no causal impact of treatment on the surrogate outcome have a causal impact on the true endpoint of interest. Instead, we have an extra complication in that the parameters of interest are not fully identifiable even in the absence of missing outcomes since only the marker and the outcome under the actual treatment assignment are observed. We also allow for the possibility that missingness has a counterfactual component, one that might differ between the treatment and control due to differential dropout, a feature that previous literature has not addressed to our knowledge.
This article proceeds as follows. Section 'Assessing surrogacy via principal stratification' develops surrogacy assessment using principal stratification, including the definitions of surrogacy measures of interest. Section 'Principal Stratification model for surrogacy accounting for nonresponse in the true endpoint' extends the principal stratification model for surrogacy to account for missing data using both latent ignorable and missing completely at random (MCAR) models, and discusses the use of the decision information criterion (DIC) measure to choose between the models. Section 'Simulation study' considers the reduction in bias and mean square error when missing data methods are employed via a simulation study. Section 'Application to the Collaborative Initial Glaucoma Treatment Study' applies the proposed methods to a study of intraocular pressure (IOP) in glaucoma patients, using early measures of IOP as a surrogate marker for later measures of IOP to assess the effect of surgical versus drug treatment. We conclude with a summary discussion in section 'Discussion'.
Assessing surrogacy via principal stratification Notation
We denote treatment assignment by Z l , the potential outcome for the surrogate under each of the treatment assignments for the lth subject by S l (Z l ), and the potential outcome for the true endpoint under each of the treatment assignments by T l (Z l ). We assume that the surrogate is fully observed but that the true endpoint under the assigned treatment arm is missing (e.g., due to insufficient follow-up time or dropout), and denote R l (Z l ) = f0, 1g corresponding to missing and observed true endpoints under each of the treatment assignments, respectively. Assuming dichotomous treatment assignments, surrogate markers, and true endpoints, the support for the joint distribution of the potential outcomes of the true endpoints is given by f(0, 0), (0, 1), (1, 1), (1, 0)g, corresponding to failure under both arms, failure under control and success under treatment, success under both arms, and success under control and failure under treatment, respectively. Potential surrogate markers and responses have similar support corresponding to success/failure or observed/missing associated with each treatment arm. We denote the probability of a subject belonging to a cell in the resulting 4 3 4 3 4 contingency table by P((S(0), S(1)) = i, (T(0), T(1)) = j, (R(0), R(1)) = k) = p ijk , where i, j, k = f1, 2, 3, 4g, corresponding to the four support points (see Table 1 ). Thus, the 'complete data' are f(S(0), S(1)) l , (T(0), T(1)) l , (R(0), R(1)) l , l = 1, . . . , ng. The observed data for the lth subject are given by (z l , r l , s l , t l ), where r l = R(Z l = z l ), s l = S(Z l = z l ), and
Surrogacy measures of interest
The principal strata correspond to the categories associated with the distribution of the potential surrogate markers, with (0,0) termed 'never responsive', (0,1) termed 'responsive', (1,1) termed 'always responsive', and (1,0) termed 'harmed', where without loss of generality, 0 corresponds to a 'poor health' surrogate marker and 1 to a 'good health' surrogate marker. Under the assumption of 'monotonicity', corresponding to no one harmed with respect to either the surrogate or outcome, the overall CE is given by E(T l (1) À T l (0)) = p +2 = p 12 + p 22 + p 32 . (Here and later in the article, we denote p ij [p ij+ = P k p ijk as the joint distribution of the potential surrogate marker and potential outcome marginalized across the missingness patterns.) Frangakis and Rubin [14] proposed associative and dissociative effects corresponding, respectively, to the fraction of patients on which the treatment changed both the surrogate marker and the final outcome AE = p 22 and the fraction of patients on which the treatment changed the surrogate marker but not the final outcome DE = p 12 + p 32 . A good surrogate will have a large AE, indicating that the CE on the surrogate is highly associated with a CE on the final outcome of interest. Similarly, a good surrogate will have a small DE, indicating that the CE on the outcome is small when the CE on the surrogate is zero. (Note that since the surrogate and outcome are not manipulated separately in the principal stratification framework, associative effects cannot be interpreted as indirect effects from the treatment through the surrogate as defined by Ref. [10] .) Because AE and DE are constrained to sum to CE, interpreting 'large' and 'small' is perhaps most useful relative to the CE; hence, Taylor et al. [11] defined associative proportion (AP) = AE/CE and dissociative proportion (DP) = DE/CE as the fraction of the overall treatment effect partitioned between the associative and dissociative effects. Li et al. [16] proposed another surrogacy measure, common associative proportion (CAP) = p 22 = p 12 + p 21 + p 22 + p 23 + p 32 ð Þ , suggested by the concept of 'perfect surrogacy' [14] , which would occur when there is no CE on T unless there is also a CE on S (i.e., p 12 = p 32 = 0). Without the monotonicity assumption, CE = p +2 À p +4 (the net treatment effect corresponding to the fraction responsive to the treatment minus the fraction harmed), AE = p 22 + p 42 À (p 24 + p 44 ) (net treatment effect on patients whose surrogate was responsive to treatment), and DE = p 12 + p 32 À (p 14 + p 34 ) (net treatment effect on patients whose surrogate was not responsive to treatment) [26] , and AP and DP are unchanged. The CAP does not have a clear analog when monotonicity is relaxed, although larger values of p 22 =p 2 + compared with p 12 =p 1+ , p 32 =p 3+ , and p 42 =p 4+ would generally be required for a good surrogate [26] .
Principal stratification model for surrogacy accounting for nonresponse in the true endpoint

Model assumptions
Factoring the joint distribution of the complete data (i.e., assuming we could observe treatment assignments, surrogate markers, true endpoints, and response behavior on both treatment arms), we obtain
for T(Z) = (T 1 (Z), . . . , T n (Z)), where T l (Z) refers to the set of potential outcomes for the lth subject associated with all possible treatment assignments Z in the sample, and similarly for S(Z) and R(Z).
We make the following three assumptions throughout the remainder of this article:
(1) Randomization. Treatment assignment is made independently of the potential outcomes for the surrogate markers, so that
also the observed surrogate marker is equal to the potential outcome under the observed treatment arm (s l = z l S(z l ) + (1 À z l )S(z l )), and similarly for T l . Table 1 . Joint distribution of potential surrogate marker, outcome, and missingness patterns (3) Latent ignorability of missing data: Conditional on the joint distribution of the surrogate markers under both treatment assignments S l (Z l ) [22] [23] [24] [25] , the joint distribution of the true endpoint under both treatment assignments T l (Z l ) is independent of the counterfactual missingness pattern R l (Z l ). Thus, we have
We also consider a MCAR model in which missingness is independent of both the surrogate and the true outcome
Note also that we do not make the compound exclusion restriction (CER). Under CER, S l (0) = S l (1) implies that R l (0) = R l (1) and T l (0) = T l (1) [22, 23] . Doing so would imply that subjects who had no causal impact of treatment on the surrogate outcome would have no causal impact of treatment on either the true endpoint of interest or on their response behavior, thereby assuming away the key issue that we would like the data to speak to in our analysis.
We also consider the models with and without the monotonicity assumption for surrogate marker and true endpoint. Under monotonicity, subjects will never have a negative CE, so that P(S l (0) = 1, S l (1) = 0) = P(T l (0) = 1, T l (1) = 0) = 0. Here, we also consider a more limited form of monotonicity, which we term 'stochastic monotonicity', that only assumes that the treatment is more likely to be helpful than harmful (p 2 + + .p 4 + + ) for the surrogate measures, and that within the nonharmful principal strata, the treatment is more likely to be helpful than harmful (p j2+ .p j4+ , j = 1, 2, 3) for the final outcome [28] .
Finally, the counterfactual missingness patterns might be restricted by knowledge about the missingness mechanism. For example, if dropout is entirely due to administrative censoring, it might be reasonable to assume that the missingness value observed on the assigned treatment arm might be equivalent to the missingness value on the unassigned arm, so R(Z) 2 f(0, 0), (1, 1)g (i.e., p + + 2 = p + + 4 = 0), and thus, the missingness pattern is fully observed. We do not pursue these restrictions further.
Model estimation
Latent ignorability model
we have under the latent ignorability assumptions that p jjik [p jji for all k, reducing the number of free parameters in the complete data from 63 to 27: 12 free parameters for p jji and 15 free parameters for p i + k . (Under monotonicity, p j = 4ji = 0 for all i and p 4 + k = 0 for all k, further reducing the number of free parameters in the complete data to 17.) However, there are only 10 sufficient statistics in the observed data: six for the observed S 3 T tables stratified by Z when R = 1, two for the observed S stratified by Z when R = 0, and two for the observed R 3 Z table. Hence, we use a fully Bayesian approach to cope with the nonidentifiability in the observed data likelihood [29] [30] [31] .
The complete data likelihood is given by
We assume a Dirichlet prior for the cell probabilities
Details of the Gibbs sampler are given in Appendix A.
MCAR model
Under the MCAR assumption, p((S(0), S(1)) = i, (R(0), R(1)) = k) = p((S(0), S(1)) = i)p((R(0), R(1)) = k), and thus, p ijk = p jji p i + + p + + k = p ij+ p + + k . The distribution of R is thus independent of S and T and thus can be ignored in both the data augmentation step and the draw of the parameters conditional on the complete data for estimation of the surrogacy effects of interest (although required to obtain model fit estimates discussed in section 'Choosing between the missingness mechanisms'). We again assume a Dirichlet prior for the cell probabilities
Choosing between the missingness mechanisms
To choose between the latent ignorable and MCAR missingness mechanisms, we can compute the Deviance Information Criterion (DIC) of Spiegelhalter et al. [32] . The DIC measure accounts for the fact that, in a hierarchical framework, the number of effective parameters may be unclear: the random effects associated with each subject may 'count' as approximately one parameter if the between-variance estimates are large (small degree of shrinkage), and as nearly zero parameters if the between-variance estimates are small (large degree of shrinkage). DIC estimates the number of effective parameters by p D = D(p) À D(p), where D(p) = E pjy D(p) and D(p) = D(E(pjy)) for the observed likelihood deviance D(p) given in Appendix A. The DIC measure is then given by D(p) + 2p D . Although we do not entertain a Bayesian hierarchical model here, we have a similar issue in that the number of parameters is unclear given that not all are fully identified. We will assess the effectiveness of DIC in choosing between the latent ignorable and MCAR missingness mechanisms via simulation.
Simulation study Study design
Although our estimation approach is Bayesian, assessing its frequentist properties is important for model assessment [33] . Hence, we conduct a simulation study using a 2 3 2 3 2 design, where the surrogate is either poor or good as measured by the APs and CAPs, where the principal strata are either independent of or associated with missingness (corresponding to ignorable and nonignorable missingness mechanisms), and where missingness is either independent of treatment or more likely if assigned to treatment. For each simulation, we fit both the latent ignorable model and the MCAR model as well as a model that uses the complete cases only, and compute the bias and root mean square error (RMSE) of the posterior mode, nominal 90% coverage, and mean 90% credible interval length, for the CE, AP, and CAP. We use 10,000 draws from a Markov chain Monte Carlo (MCMC) chain after 1000 draws for burn-in. Each simulation contains 500 observations, and 200 simulations are run for each scenario in the design. The missingness mechanism is designed to provide approximately 50% missing for each scenario. For each scenario, we also compute the DIC under both the latent ignorable and MCAR model. We restrict our simulations to the monotonicity setting to minimize the complexity of the simulation design and focus on the properties of interest. Table 2 provides details of the simulation design. Under the ignorable model, the principal strata are independent of missingness. Under the nonignorable model, the odds of a subject belonging to an 'always responsive' surrogate marker principal strata versus a 'never responsive' surrogate marker principal strata are approximately four times greater when the outcome is observed under control than when it is missing under control. The marginal distribution of the missingness patterns is defined by p + +1 = Á Á Á = p + + 4 = :25 when missingness is independent of treatment, and by p + +1 = :15, p + + 2 = :15, p + + 3 = :15, p + + 4 = :55, when missingness is more likely under treatment.
We assume two forms of the prior: a uniform Dirichlet prior, with a 1j1 = Á Á Á = a 3j3 = 1 and Table 3 shows the results from data generated under the nonignorable simulation, while Table 4 shows the results from data generated under the ignorable simulation. We summarize the results as follows:
Results
When the design is nonignorable, using the MCAR model leads to increased bias and RMSE relative to the latent ignorable model for all three estimators considered. This is true even for the CE estimator, which is fully identified. This impact of model misspecification is strongest on CE for the 'good' surrogate (large AP/CAP) and on AP for the 'poor' surrogate (small AP/CAP).
Using the latent ignorable model has little impact on bias or RMSE when design is ignorable. When the design is nonignorable, the CE estimator has reduced bias and improved coverage under either of the missing data models relative to the complete-case analysis, with this difference being stronger when the surrogate is poor than when it is strong. Under the ignorable design, use of the latent ignorable model yields a slightly greater mean square error (MSE) than the complete-case analysis, although coverage is also improved. Coverage for AP and CAP tends to be conservative because of partial identification; use of the latent ignorable model helps ensure that coverage does not become anticonservative. Coverage for AP and CAP is poor for the completecase analysis, especially under nonignorable missingness with a good surrogate. * Although the CE is fully identified in the absence of missing data, the need to rely on incompletely identified parameters means that the 90% confidence interval (CI) under the missing data models is actually wider than an analysis using the fully observed data only, with the coverage becoming highly conservative when the surrogate is poor. Lack of identification induces bias in the AP and CAP estimators when the surrogate is poor because posterior distributions are relatively flat. Use of less informative prior reduces bias, at the cost of increased RMSE and CI length. DIC always picks the latent ignorable model when correct. DIC picks the MCAR model majority of the time (60%-80%) when correct, with high values of AP/CAP allowing the MCAR model to be selected with greater probability when it was correct.
Application to the Collaborative Initial Glaucoma Treatment Study
We apply the missing data models to an analysis of the Collaborative Initial Glaucoma Treatment Study (CIGTS) [35] . Glaucoma is an eye disease caused by increased IOP that can result in reduced vision or blindness. The CIGTS was a clinical trial that compared the effects of eye surgery (treatment) against the standard practice of medication (control) to reduce or stop visual field loss. Because visual field loss is caused by increased IOP, one of the major secondary outcomes of interest is reduction in IOP. Here, we consider reduction in IOP below 18 mmHg after 96 months of follow-up, based on previous work that has shown that IOP of less than 18 mmHg at every time point during at least 6 years of followup was associated with a reduced likelihood of visual field loss [36] . Because of the extensive follow-up * As noted in Gustafson and Greenland [34] , Bayesian credible intervals have by definition correct coverage regardless of the sample size and model identification when the parameters are generated under the assumed prior. However, because nonidentified models converge to regions of 0 and nonzero posterior probability rather than degenerate atoms [31] , if we take a frequentist perspective where the true values of the data are fixed, the resulting credible intervals will have frequentist coverage properties that will approach 1 if the data-generating model is correct unless the true value of the interval is on the boundary of the nonzero posterior probability region [28] . time, we wish to determine whether early reductions in IOP could serve as a marker for much late reductions; hence, the surrogate marker was reduction in IOP below 18 mmHg after 12 months of follow-up. However, such an analysis suffers from a substantial amount of missing outcome data due to the long follow-up period. Because the cause of the missingness is due to dropout for unknown reasons, we do not restrict the missingness patterns in the analysis. The observed data are given in Table 5 . Of 574 subjects with IOP measured at 12 months, only 228 had fully observed data (IOP also measured at 96 months). For fully observed subjects in the control arm (drug only), 66.7% had reduced IOP to below 18 mmHg at 96 months; 79.4% of fully observed subjects on the treatment arm had reduced IOP at 96 months, giving an estimated CET of .127 (90% CI: .030, .224). Reduced IOP at 12 months was observed for 58.4% of subjects who were fully observed on the control arm versus 54.8% of subjects who did not have 96-month IOP measures. For subjects on the treatment arm, 80.4% of fully RMSE: root mean square error; CE: causal effect; CAP: common associative proportion; AP: associative proportion; MCAR: missing completely at random; DIC: decision information criterion; CI: confidence interval. Independent nonresponse = missingness equally likely under treatment and control, dependent nonresponse = missingness more likely under treatment; poor surrogate = small associative proportion, good surrogate = large associate proportion (see Table 2 ). Top line gives result under uniform prior; lower line gives result under Jeffreys-type prior. Reduced IOP at 12 months  No  28  29  69  145  11  8  35  65  Yes  14  55  97  147  10  73  144  216  42  84  166  292  21  81  179  282   IOP: intraocular pressure. observed subjects had reduced IOP at 12 months versus 81.4% of subjects without the 96-month IOP measures.
We fit a MCAR model and a latent ignorable model, as well as a model for the fully observed data, under the monotonicity and nonmonotonicity assumption, as well as the 'stochastic monotonicity' assumption that only assumes the treatment more likely to be helpful than harmful. Each model is fit using a single chain of 100,000 draws after a burn-in of 1000. We consider uniform priors using the Dirichlet distribution with a jji = 1 for all i, j and b i + k = 1 for all i, k for the latent ignorable model and a ij+ = 1 for all i, j and b + + k = 1 for all k for the MCAR model. We assess sensitivity to the prior by considering a Jeffreys-type prior using the Dirichlet distribution with a 1j1 = Á Á Á = a 4j4 = 1=2 and b 1 + 1 = Á Á Á = b 4 + 4 = 1=2 and a 11 + = Á Á Á = a 44 + = 1=2 and b + +1 = Á Á Á = b + + 4 = 1=2. Results are given in Table 6 . Table 7 provides the DIC measures for the latent ignorable and MCAR models.
Based on DIC, the best fit is provided by the latent ignorable model under stochastic monotonicity; similar fit is provided by the MCAR model under monotonicity and the uniform Dirichlet prior. Particularly poor fit is evidenced by the MCAR model under nonmonotonic assumptions, as evidenced by the discrepancy between the CE estimator from the model and the identifiable estimate (.127) obtained from the fully observed data; use of the Jeffreys-type prior improved the fit to some degree. The best-fitting latent ignorable model under stochastic monotonicity and MCAR model under monotonicity had little sensitivity to the prior assumptions, and gave broadly similar results. In particular, early reduction of IOP appears to be at best a modestly useful surrogate marker from a causal perspective, with only a weak association between the 8-year CE on IOP and the 12-month CE on IOP. The point estimate of the AP is somewhat greater under the stochastic monotonicity assumption than under the full monotonicity assumption, although the 90% credible interval can and does include 0, indicating some evidence of interactions in the CE outcomes within the principal strata [28] . The best model fit was obtained under the latent ignorable model with the stochastic monotonicity assumption and the Jeffreys-type prior; Figure 1 shows the associated posterior distributions of the CE, AE, and AP under this model. The overall degree of model fit is assessed via the posterior predictive distribution of functions T of the observed values of y l given by p(T(y rep l )jy) = ð p(T(y rep )jp, y)p(pjy)dp ð1Þ
We obtain draws from Equation (1) and compare the predictive distribution T(y rep ) with the observed values of T(y obs ) [37] . In particular, we consider the eight cell counts of surrogate marker and outcome by treatment assignment given by m ijz = P l I(s l = i, t l = jjz l = z) for i, j, z 2 f0, 1g; histograms of m rep ijz compared against m obs ijz in Figure 2 show that the predictive distributions are centered near the observed values, showing that the model is reasonable, given the data.
In general, the lack of large differences in the surrogate marker treatment effects between the outcome response categories suggests that failing to account for missingness in the outcome should have modest impact, and indeed, this is the case where model fit is reasonable (under monotonicity, and in the nonmonotonic models with the Jeffreystype priors). Estimates for the CE, AE, and AP appear to be smaller in the fully observed data than in the models that incorporate missing outcome data, consistent with the mechanisms that lead to negative bias for these estimates in the simulation setting. Intervals for models that incorporate missing outcome data are somewhat wider than intervals that discard this data, consistent with the fact that accounting for missingness requires estimation of not fully identified parameters.
Discussion
This article considers a principal stratification approach to assess surrogacy for dichotomous markers and outcomes when missing data are present for the outcome, extending the work of Li et al. [16] to accommodate missingness under latent ignorability assumptions. The principal strata are defined by the joint distribution of the surrogate marker under both treatment and control, with the quality of the surrogate being the CET that is associated with strata in which the surrogate marker is impacted by treatment. Latent ignorability assumes that the conditional distribution of the potential outcomes within the principal strata is independent of the outcome missingness but allows for the possibility that the marginal distribution of the surrogate marker or treatment outcome is associated with outcome missingness. This is a weaker assumption than MCAR in which missingness is independent of both the surrogate and the true outcome, and is identifiable at the 'complete data' (counterfactual) level, in contrast to a fully nonignorable model, which would require postulating nonidentified parameters for the unobserved outcomes at this complete-data level. A unique aspect of our approach (to our knowledge) is that we allow for the possibility that missingness has a counterfactual component, one Principal surrogacy with missingness 373 that might differ between the treatment and control due to differential dropout. Alternatives to the latent ignorability missingness mechanisms can be considered as well. A special case of latent ignorability would be a 'fully ignorable' missingness mechanism in which missingness depends only on observed data, so that the complete data could be factored as P((T(0)T(1))j(S(0)(1)))P((S(0), S(1)))P((R(0), R(1))jS(z)), where z is the observed treatment arm. Chen et al. [24] propose a 'completenonignorability' model, which is identified under the complete data using the selection model decomposition, replacing P(R l (Z l )jT l (Z l ), S l (Z l )) = P(R l (Z l )jS l (Z l )) under latent ignorability with P(R l (Z l )jT l (Z l ), S l (Z l )) = P(R l (Z l )jT l (Z l )) to yield p(T l (Z l )jS l (Z l )) p(S l (Z l ), R l (Z l )) = p(R l (Z l )jT l (Z l ))p(T l (Z l ), S l (Z l )).
There are two major limitations in this approach that result from lack of full identifiability. First and foremost, we suffer from sensitivity to prior assumptions even in large data sets, since the posteriors do not converge in distribution to normal distributions centered at their likelihood modes. Second, posterior credible intervals are typically fairly wide and cannot shrink beyond asymptotic boundary conditions. Thus, even mildly informative priors can introduce nontrivial bias in moderate sample size settings, while more 'noninformative' priors can yield credible intervals of very large widths. Hence, this article has focused on exploring the sensitivity and identifiability aspects of these inherently nonidentified models. We also note that avoiding these limitations by using fully identified models requires making stronger assumptions that are not warranted by the inferential question we are addressing.
A variety of extensions to this work can be considered. Our focus is on assessing and ameliorating the effect of missingness on inference about binary surrogate measures and outcomes in a counterfactual setting, and in the process, we have focused on a relatively simple Dirichlet prior formulation for the cell parameters. The work of Li et al. [16, 26] considered a log-linear parameterization that was capable of incorporating a priori assumptions about positive correlations between the surrogate marker and final outcome in a more refined fashion than the model considered here, particularly when the monotonicity assumption is relaxed. Extensions to continuous surrogate measures and outcomes are also possible and are the focus of the current work. The data augmentation step for T(Z l ) remains as in the latent ignorable selection model.
Observed likelihood deviance
The observed likelihood deviance D(p) (up to a constant) is given by À2( 
